Archive

May 2025

Browsing

Macy’s cut its full-year profit guidance on Wednesday even as it beat Wall Street’s quarterly earnings expectations, as the retailer’s CEO said it will hike prices of certain items to offset tariffs.

In a news release, the department store operator said it reduced its earnings outlook because of higher tariffs, more promotions and “some moderation” in discretionary spending. Macy’s stuck by its full-year sales forecast, however.

For fiscal 2025, Macy’s now expects adjusted earnings per share of $1.60 to $2, down from its previous forecast of $2.05 to $2.25. It reaffirmed its full-year sales guidance of between $21 billion and $21.4 billion, which would be a decline from $22.29 billion in the most recent full year.

In an interview with CNBC, CEO Tony Spring said about 15 cents to 40 cents per share of the guidance cut is due to tariffs. He said about 20% of the company’s merchandise comes from China.

Macy’s will raise some prices and stop carrying certain items to mitigate the hit from tariffs, he added.

“You’re dealing with it on both the demand side as well as the increased cost side,” he said. “And so navigating that, we have a series of different scenarios to try to figure out kind of what will be the reality, and we want our guidance to reflect the flexibility of that uncertainty, so that we can react in real time to how we serve or better serve the consumer.”

Spring said the company will be “surgical” with price changes.

“It’s not a one-size-fits-all kind of approach,” he said. “There are going to be items that are the same price as they were a year ago. There is going to be, selectively, items that may be more expensive, and there are items that we might not carry because the pricing doesn’t merit the quality or the perceived value by the consumer.”

Here’s how Macy’s did during its fiscal first quarter, compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

In the three-month period that ended May 3, the company’s net income was $38 million, or 13 cents per share, compared with $62 million, or 22 cents per share, in the year-ago period. Sales dropped from $4.85 billion in the year-ago quarter. Excluding some one-time charges including restructuring charges, adjusted earnings per share were 16 cents.

The company’s shares were down more than 2% in early trading on Wednesday.

Economic uncertainty — including President Donald Trump’s on-again, off-again tariff announcements — has complicated Macy’s turnaround plans. The New York City-based legacy retailer is more than a year into a three-year effort to become a smaller, but healthier business. It’s shuttering weaker stores and investing in stronger parts of the company, including luxury department store Bloomingdale’s and beauty chain Bluemercury. It has also tried to improve the customer experience, including by speeding up online deliveries and adding staff to stores.

Spring told analysts on the earnings call that the tariff impact on Macy’s outlook includes the additional costs of inventory previously imported under the 145% China tariffs, which have since dropped to 30%. He said the outlook does not include a potential increase in tariffs on the European Union or any other U.S. trading partner.

Trump recently threatened to implement, and then delayed, a 50% tariff on the EU.

Macy’s sells a mix of national band private brands, which are sold exclusively at its stores and on its website. Spring told CNBC that the company has reduced the share of its private brands that comes from China to about 27% — a drop from 32% last year and more than 50% before the Covid pandemic.

CFO Adrian Mitchell said on the company’s earnings call that Macy’s has taken action to blunt the impact of tariffs on national brands it sells, too. He said the company has renegotiated orders with vendors, canceled some orders and delayed others.

“We’ve been able to gain some vendor discounts, which has been helpful to us, but we’re absorbing some of that price as well,” he said.

And in some cases, Macy’s is keeping prices the same despite higher costs to appeal to value-conscious customers and gain market share from competitors, Mitchell added.

Spring said on the company’s earnings call on Wednesday that Macy’s sales were stronger in March and April compared to February, attributing some of that to improving weather. So far, sales trends in the second quarter have been above those in March and April, he added.

Macy’s plans to close about 150 underperforming namesake stores across the country by early 2027.

In the fiscal first quarter, Macy’s namesake brand remained its weakest. Comparable sales across Macy’s owned and licensed business, plus its online marketplace, declined 2.1% year over year.

When Macy’s took out the stores that it plans to shutter, however, trends looked slightly better. Comparable sales of its go-forward business, including its owned and licensed business and online marketplace, declined 1.9%

On the other hand, comparable sales at Bloomingdale’s rose 3.8% year over year, including its owned, licensed and marketplace businesses. Comparable sales at Bluemercury climbed 1.5% year over year.

To try to turn its namesake stores around, Macy’s has invested in 50 locations — dubbed the “First 50” — with more staffing, sharper displays and changes to its mix of merchandise. It has expanded that initiative to 75 additional stores, bringing the total to 125 locations that have gotten increased attention. That’s a little over a third of the 350 namesake locations that Macy’s plans to keep open.

Those 125 locations performed better than the overall Macy’s brand. Comparable sales among those revamped stores owned and licensed by Macy’s were down 0.8% compared with the year-ago period.

On Macy’s earnings call in March — before Trump made several sudden tariff moves that baffled companies and investors — Spring said the company’s guidance “assumes a certain level of uncertainty” about the economic outlook. He said even Macy’s affluent customer “is just as uncertain and as confused and concerned by what’s transpiring.”

Earlier this spring, Macy’s announced a few key leadership changes — including a new chief financial officer. Macy’s new CFO, Thomas Edwards, will begin on June 22. He previously served as the chief financial officer and chief operating officer of Capri Holdings, the parent company of Michael Kors. He will succeed Mitchell, who is leaving Macy’s.

As of Tuesday’s close, Macy’s shares are down about 29% so far this year. That trails the S&P 500′s nearly 1% gains during the same period. Macy’s stock closed on Tuesday at $12.04 per share, bringing the retailer’s market value to $3.35 billion.

This post appeared first on NBC NEWS

President Donald Trump’s Department of Health and Human Services (HHS) is terminating awards totaling more than $750 million dollars that were provided to pharmaceutical manufacturer Moderna to help facilitate its production of mRNA-based bird flu vaccines. 

During President Joe Biden’s final week in office, his administration awarded $590 million to Moderna to help speed up its production of mRNA-based vaccines. The $590 million award followed a separate $176 million award Biden gave to Moderna earlier last year for mRNA vaccine technology.

Messenger RNA vaccines are a newer type of vaccine technology, which was utilized by companies like Moderna and Pfizer to develop their COVID-19 vaccines. The vaccine technology was at the center of a lot of criticism amid the coronavirus pandemic for potentially being associated with adverse side effects in some people who took them, such as myocarditis.

Trump administration officials previously hinted at the potential that this funding could be terminated, citing a lack of oversight during the Biden administration pertaining to vaccine production. 

‘After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,’ HHS Communications Director Andrew Nixon said. ‘This is not simply about efficacy — it’s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.’

The announcement reflects a larger shift in federal vaccine priorities, after HHS Secretary Robert F. Kennedy Jr. announced earlier this week that COVID-19 vaccines would be removed from the federal government’s list of recommended vaccines for children and pregnant women. 

Meanwhile, a report from Senate Republicans released earlier this month suggested the Biden administration withheld critical safety data and downplayed known risks tied to the mRNA COVID-19 vaccine. In particular, the Senate report focuses on HHS’ awareness of, and response to, cases of myocarditis — a type of heart inflammation — following COVID-19 vaccination.

‘Rather than provide the public and health care providers with immediate and transparent information regarding the risk of myocarditis following mRNA COVID-19 vaccination, the Biden administration waited until late June 2021 to announce changes to the labels for the Moderna and Pfizer COVID-19 vaccines based on the ‘suggested increased risks’ of myocarditis and pericarditis,’ the Senate report states. ‘Even though CDC and FDA officials were well aware of the risk of myocarditis following COVID-19 vaccination, the Biden administration opted to withhold issuing a formal warning to the public for months about the safety concerns, jeopardizing the health of young Americans.’

In response to the Trump administration’s funding termination, Moderna put out a press release acknowledging the move, but also touting the ‘safety profile’ observed amid its work on a new mRNA bird flu vaccine.

‘While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,’ said Stéphane Bancel, Chief Executive Officer of Moderna. ‘These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.’

Fox News Digital’s Brooke Singman contributed to this report.

This post appeared first on FOX NEWS

European stock markets exhibited a cautious and mixed start to Wednesday’s trading session, with the pan-European Stoxx 600 index hovering near flat territory as investors braced for a significant influx of economic data from across the continent.

Currency markets saw both the British pound and the euro soften against the US dollar, while global attention turned towards upcoming US Federal Reserve meeting minutes and highly anticipated earnings from chip giant Nvidia.

Shortly after the opening bell, the pan-European Stoxx 600 was trading flat, reflecting a general lack of strong directional conviction among investors.

National bourses showed slight variations: London’s FTSE 100 and the French CAC 40 were marginally higher, indicating a touch of resilience.

Germany’s DAX, which had impressively scaled a record high in Tuesday’s session, was trading around 0.1% higher, suggesting it was holding onto its recent strong gains.

This tentative market mood comes as participants anticipate a swathe of economic indicators due for release throughout the day.

Key data points include German import prices, final French gross domestic product (GDP) figures, employment data from both France and Germany, and an update on Turkish economic confidence.

These releases will provide further insights into the health and trajectory of the European economy.

Currency watch: pound and euro dip against dollar

In foreign exchange markets, the British pound was trading 0.2% lower against the US dollar on Wednesday morning.

This movement put sterling on track for its second consecutive day of losses versus the greenback, though it’s important to note that the pound has still appreciated by a significant 7.7% against the dollar year-to-date.

Similarly, the euro was also trading 0.2% lower against the US currency, potentially extending its losses for a second day.

Despite this recent dip, the euro has recorded a gain of more than 9% against the US dollar since the beginning of the year.

Global focus: Fed minutes and Nvidia’s numbers awaited

Global investors are keenly awaiting the release of minutes from the US Federal Reserve’s May meeting, which are due later on Wednesday.

These minutes will be scrutinized for any fresh clues regarding the central bank’s thinking on inflation, interest rates, and the overall economic outlook.

While no major corporate earnings were expected out of Europe on Wednesday, market participants on both sides of the Atlantic are closely monitoring the upcoming earnings report from US chipmaking behemoth Nvidia.

The company’s results, due after Wall Street’s closing bell, are widely seen as a key barometer for the tech sector and broader market sentiment.

Asia-Pacific recap and US market cues

The trading backdrop from the Asia-Pacific region was mixed on Wednesday.

Japan’s Nikkei 225 was last seen trading 0.3% higher, while South Korea’s Kospi added a more substantial 1.8%.

However, Australia’s S&P/ASX 200 shed 0.2% after the country reported a higher-than-expected rise in inflation.

Hong Kong’s Hang Seng index was also down 0.4%.

On Wall Street, stock futures were flat ahead of Wednesday’s trading session.

This followed broad gains on Tuesday, as investors reacted positively to US President Donald Trump’s decision to pause the implementation of 50% tariffs on European Union imports, a development that markets absorbed as they reopened after the Memorial Day holiday.

German import prices show unexpected contraction

Adding to the day’s economic narrative, fresh data from Germany revealed an unexpected development in import prices.

Figures from the Federal Statistical Office showed that German import prices fell by 0.4% year-on-year in April.

This was a surprise, as analysts polled by LSEG data had been anticipating an annual rise of 0.2%.

The previous month, March, had seen import prices in Germany rise by 2.1%, making the April contraction particularly noteworthy.

The post Europe markets open: Stoxx 600 hovers near flatline; focus on German data, US Fed, Nvidia results appeared first on Invezz

Challenger Gold Limited (ASX: CEL) (‘CEL’ or the ‘Company’) is pleased to announce it has entered into an Investment Protection Agreement (“IPA” or “the Agreement”) with the Government of Ecuador for its 100% owned El Guayabo Project (“El Guayabo” or “the Project”). Under the terms of the IPA, the Government of Ecuador has granted CEL legal protections including stability of the regulatory framework, resolution of disputes through international arbitration, and protection of CEL’s investment.

The IPA covers US$75 million in investment from CEL encompassing expenditures from CEL’s initial acquisition of the project in 2019 and expenditure incurred until the end of 2027. It has an initial term of 8 years and is renewable. Key incentives and protections under the IPA include:

  • Regulatory stability and protection from changes to the current legal framework
  • The legal framework at the time of execution will continue to apply if the terms are more favourable to the project owner than any potential new framework
  • The IPA guarantees rights including non-discriminatory treatment, property protection, and legal certainty
  • International arbitration, should there be any disputes in relation to the Project, with the seat of arbitration in London under the rules of the International Chamber of Commerce

Commenting on the Investment Protection Agreement, CEL Managing Director, Mr Kris Knauer, said

“The completion of the Investment Protection Agreement is a significant development for the Project..

The IPA provides certainty with respect to the legal framework governing the Project, including stable mining regulations and fiscal terms, and security of title and investment for the term of the agreement. Additionally, it provides protection from all forms of confiscation and a mechanism for international arbitration should there be any disputes related to the project.

The IPA is also timely given recent corporate action in Ecuador as we take steps to monetise our Ecuador assets following the significant resource upgrade from 4.5 million ounce1 to 9.1 million ounces1,2,3.

Click here for the full ASX Release

This post appeared first on investingnews.com

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. met with Argentine President Javier Milei on Tuesday at the Casa Rosada, where both leaders reaffirmed plans to withdraw their nations from the World Health Organization (WHO) and build a new international health framework.

The meeting brought together two strong-willed political outsiders. Milei, a libertarian economist known for cutting government spending, and Kennedy, a Trump-appointed health chief skeptical of pandemic-era mandates. Both promised to challenge what they call global overreach and politicized health policy.

Argentina officially confirmed its exit from the WHO during Kennedy’s visit, following Milei’s initial announcement in February. The move aligns with President Trump’s revived pledge to pull the U.S. out of the WHO as part of his ‘Make America Healthy Again’ (MAHA) agenda.

Milei’s government blasted the WHO for what it called a failed COVID response. ‘The WHO’s prescriptions do not work because they are not based on science but on political interests and bureaucratic structures that refuse to review their own mistakes,’ the government said, referring to the group’s lockdown strategy as a ‘caveman quarantine.’

Kennedy offered support, encouraging other countries to also exit the WHO in a recent address to the World Health Assembly. He has argued the organization is compromised by foreign governments and corporate interests, and that a fresh approach is needed.

After the meeting, Kennedy posted on X: ‘I had a wonderful meeting with President Milei about the mutual withdrawal of our nations from the WHO and the creation of an alternative international health system… free from totalitarian impulses, corruption, and political control.’

Both governments say the new alliance will prioritize real science, individual freedom, and national sovereignty, pushing back against what Milei’s team calls ‘interference’ from global agencies.

The meeting also highlighted shared philosophies between the two leaders. Milei took office vowing to slash Argentina’s massive public spending. He famously carried a chainsaw during his campaign to symbolize budget cuts—and has since followed through, cutting public salaries, halting state projects, and ending energy subsidies.

His tough measures have produced results: Argentina posted its first budget surplus in nearly 15 years and sharply reduced monthly inflation.

Kennedy’s MAHA campaign echoes Milei’s anti-establishment style, but in the health sector. The Trump administration’s health agenda has focused on rolling back federal overreach, enforcing science-based policy, and promoting transparency in public health.

Tuesday’s meeting marks a deeper alignment between Argentina and the current U.S. administration. Milei has welcomed top American officials in recent months and shown clear interest in building strong ties with Washington. Now, by joining the U.S. in rejecting the WHO, Milei becomes the first foreign leader to openly back Trump’s health sovereignty push.

The decision is a major departure from Argentina’s previous international partnerships and could signal a shift for other countries weighing similar moves. Both Milei and Kennedy have framed the initiative as the start of a more accountable and independent global health network.

Critics, including some in Argentina’s opposition, warn that leaving the WHO could limit access to funding and vaccines. Global health experts largely defend the WHO’s role, despite acknowledging its COVID missteps.

The U.S. Department of Health and Human Services did not immediately respond to Fox News Digital’s request for comment.

This post appeared first on FOX NEWS

Samsung is actively pursuing strategic moves on multiple fronts to bolster its technological prowess and market reach, with its investment arm reportedly in talks to back US health-care innovator Exo Imaging Inc., even as Samsung Electronics finalizes a major acquisition in the HVAC sector.

Samsung Electronics Co.’s investment division, Samsung Ventures Investment Corp., is reportedly among a consortium of firms looking to invest in Exo Imaging Inc., a US-based company specializing in health-care software and devices.

According to people familiar with the matter who spoke to Bloomberg, Samsung Ventures may participate in a private fundraising round for Exo.

This round is said to be led by Sands Capital, Bold Capital, and Qubit Health Capital.

The sources, who requested anonymity due to the private nature of the information, indicated that Santa Clara, California-based Exo could secure approximately $100 million in total funding from this round.

In a significant development tied to this potential investment, Qubit Health Chairman Omar Ishrak is also reportedly set to join Exo’s board.

Ishrak brings a wealth of experience to the role, having previously served as chief executive officer at Medtronic Plc and headed General Electric Co.’s health-care business.

Furthermore, Exo is said to be in discussions for a potential partnership with Samsung Medison Co., a Samsung subsidiary renowned for its ultrasound diagnostic devices and its sales of digital X-ray systems and scanners.

These discussions, along with the investment details, are reportedly ongoing, and the specifics could change, the people familiar with the matter cautioned.

When approached for comment, Samsung declined, while Exo, Sands Capital, Bold Capital, and Qubit Health Capital did not respond to requests. Ishrak also did not immediately respond.

Samsung Electronics acquires FläktGroup for €1.5 billion

In a separate but significant strategic maneuver, Samsung Electronics announced on May 14 its agreement to acquire all shares of FläktGroup, a leading global provider of Heating, Ventilation, and Air Conditioning (HVAC) solutions, from European investment firm Triton for €1.5 billion.

This acquisition underscores Samsung’s commitment to expanding and fortifying its presence in the rapidly growing global applied HVAC market.

“Through the acquisition of FläktGroup, an applied HVAC specialist, Samsung Electronics has laid the foundation to become a leader in the global HVAC business, offering a full range of solutions to our customers,” stated TM Roh, Acting Head of the Device eXperience (DX) Division at Samsung Electronics.

Our commitment is to continue investing in and developing the high-growth HVAC business as a key future growth engine.

FläktGroup, headquartered in Herne, Germany, boasts over a century of technological expertise and design capabilities.

The company offers a diverse range of products and solutions tailored to various customer needs, supplying high-reliability and high-efficiency HVAC systems to a wide array of buildings and facilities.

These include critical environments such as data centers requiring stable cooling, museums and libraries managing sensitive historical artifacts, high-traffic airports and terminals, and large hospitals where hygiene, temperature, and humidity control are paramount.

FläktGroup’s strength in data centers and specialized industries

FläktGroup has established a strong reputation in the global large-scale data center market, achieving high customer satisfaction through its product performance, reliability, and service support.

This has translated into substantial revenue growth for the company over the past three years.

FläktGroup’s data center solutions feature industry-leading liquid cooling and air cooling products, which have enabled customers to reduce energy consumption and contribute to achieving lower carbon footprint goals.

Last year, FläktGroup’s innovative technologies were recognized with the DCS Cooling Innovation of the Year Award at the DCS Cooling Awards.

Trevor Young, CEO of FläktGroup, expressed enthusiasm about the acquisition:

We are extremely pleased that FläktGroup has become a part of Samsung Electronics. FläktGroup, as a global top-tier HVAC specialist with over a century of expertise, has been relied on by global large clients for its technological and product innovations. Now, with Samsung Electronics’ global business foundation and investment, we expect to further accelerate our growth.

Beyond data centers, FläktGroup has cultivated a diverse portfolio of over 60 large customers, including leading pharmaceutical companies, biotech and food and beverage firms, and gigafactories, showcasing its broad market applicability and established client base.

The post Samsung to invest in US health-care software and device company Exo? What we know appeared first on Invezz

Here’s a quick recap of the crypto landscape for Monday (May 26) as of 9:00 p.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$109,039 as markets closed, up 1.2 percent in 24 hours. The day’s range for the cryptocurrency brought a low of US$109,003 and a high of US$110,162.

Bitcoin performance, May 26, 2025.

Chart via TradingView.

Ethereum (ETH) finished the trading day at US$2,540.88, a 0.7 percent increase over the past 24 hours. The cryptocurrency reached an intraday low of US$2,534.30 and saw a daily high of US$2,567.88.

Altcoin price update

  • Solana (SOL) closed at US$174.15, up 1.1 percent over 24 hours. SOL experienced a low of US$174.12 in the final minutes of trading and reached a high of US$178.07.
  • XRP is trading at US$2.31, reflecting a 0.2 percent increase over 24 hours. The cryptocurrency reached a daily low of US$2.30 and a high of US$2.33.
  • Sui (SUI) peaked at US$3.47, showing a decreaseof 1.9 percent over the past 24 hours. Its lowest valuation on Monday was US$3.59.
  • Cardano (ADA) is trading at US$0.7549, up 0.9 percent over the past 24 hours. Its lowest price of the day was US$0.7547, and it reached a high of US$0.7688.

Today’s crypto news to know

Could soaring debt send Bitcoin to US$1 million by 2030?

Prominent voices are calling for US$1 million Bitcoin by the end of the decade, a Cointelegraph post shows.

ARK Invest CEO Cathie Wood sees Bitcoin hitting US$1.5 million by 2030 in a high-conviction ‘bull case’ scenario, driven upward by institutional adoption and the coin’s unique monetary properties.

Robert Kiyosaki has echoed the million-dollar prediction, linking it to surging US debt and potential economic collapse, which he says will push investors to safe-haven assets like Bitcoin, gold and silver.

“I strongly believe, by 2035, that one Bitcoin will be over US$1 million, Gold will be US$30,000, and silver US$3,000 a coin,” the financial author posted on X, formerly Twitter, in mid-April.

“We have been quite bullish over the last five or six weeks. We have been bearish coming out of the Trump inauguration in February, but we turned quite bullish,” 10x Research CEO Markus Thielen told Cointelegraph on May 22.

If momentum continues, 2025 could mark Bitcoin’s most aggressive bull run to date. Still, volatility remains a key wildcard, especially as political and macroeconomic dynamics evolve.

Trader behind US$1 billion Bitcoin bet goes all in on PEPE memecoin

Pseudonymous trader ‘James Wynn,’ better known as “moonpig” on the decentralized exchange Hyperliquid, has become one of the most talked-about crypto traders after flipping from a billion-dollar Bitcoin bet to a US$1 million leveraged bet on memecoin PEPE. Days ago, Wynn closed a US$1.2 billion Bitcoin long position with a US$17.5 million loss, then doubled down on a US$1 billion short position using 40x leverage, netting US$3 million as Bitcoin dipped.

After posting about US$25 million in total profit from his trading spree, Wynn announced he’s walking away from perpetual trading. This type of trading involves derivatives contracts without an expiry date.

His latest PEPE trade, however, has already gained US$500,000 as the token jumped 6 percent in just a few hours.

The on-chain transparency of Wynn’s trades has captivated X users, turning him into a meme icon.

Strategy acquires more Bitcoin, faces legal challenges

Michael Saylor’s Strategy (NASDAQ:MSTR) has acquired an additional 4,020 BTC.

They were purchased between May 19 and 23 for US$427.1 million, as per a Monday announcement. These latest purchases were made at an average price of US$106,237 per BTC.

This marks Strategy’s fourth Bitcoin acquisition in May, bringing its total holdings to 580,250 BTC, acquired for approximately US$40.6 billion at an average price of US$69,979 per coin.

This Bitcoin acquisition occurred after Strategy director Jarrod Patten sold 2,650 Strategy shares worth nearly US$1.1 million between May 16 and 21, according to a report filed by Strategy on May 22.

Meanwhile, Strategy’s shares were down by over 10 percent last week, falling after a class-action lawsuit filed on May 16 alleged the misrepresentation of Bitcoin investments. The plaintiffs are seeking to recover losses for shareholders purportedly affected by securities fraud between April 2024 and April 2025.

Trump Media’s potential US$3 billion crypto acquisition plan

Trump Media and Technology Group (NASDAQ:DJT) is planning to raise US$3 billion to buy Bitcoin and other cryptocurrencies, according to a Monday report from the Financial Times.

According to the report, which cites six anonymous insiders, Trump Media is aiming to raise US$2 billion in fresh equity and another US$1 billion through a convertible bond.

ClearStreet and BTIG are among the brokers that could serve as underwriters on the deal.

The official announcement could come during Bitcoin 2025, taking place in Las Vegas this week. US Vice President JD Vance, Donald Trump Jr. and Eric Trump are expected to make appearances, along with David Sacks. The Bitcoin 2024 conference, which was held in Nashville, was where Trump made a highly publicized announcement about making the US the crypto leader of the world, a major turning point for his engagement with the crypto community.

Neither the Trump administration nor representatives for Trump Media have confirmed the story.

Musk starts X Money beta testing

Elon Musk has begun beta testing of X Money, a payment and banking app he is building into his social media platform X. The news was confirmed via social media post on Sunday (May 25) from an account called Tesla Owners Silicon Valley, which is not owned or operated by Musk or by Tesla (NASDAQ:TSLA); however, Musk confirmed the test, writing that access will be “very limited” due to the “extreme care” that must be taken with users’ savings.

The features and functionalities of X Money during this initial beta testing phase remain undisclosed, but integration of a payment and banking app into X represents a significant step toward Musk’s vision of an “everything app.’

Pakistan to dedicate 2,000 MW to Bitcoin mining, AI infrastructure

Pakistan’s finance ministry announced that it will allocate 2,000 megawatts (MW) of electricity to power Bitcoin-mining and artificial intelligence data centers. The initiative is being spearheaded by the government-backed Pakistan Crypto Council and is part of a national plan to monetize surplus electricity and modernize the economy.

Officials say the plan will not only alleviate grid imbalances, but also create tech-focused jobs and attract foreign investment. This marks one of the most ambitious state-backed crypto infrastructure moves by a developing country.

If successful, it could help position Pakistan as a regional hub for digital assets and artificial intelligence development. It also comes amid wider energy reforms aimed at revitalizing the nation’s troubled power sector.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Despite assurances from Trump administration officials that farmers will not be impacted by its attempts to reduce environmental chemical exposure from foods, agricultural leaders have been expressing concern that the move will explode costs for farmers and more than double the cost of food. 

The administration’s Make America Healthy Again (MAHA) Commission, made up of many of President Donald Trump’s political appointees and closest policy advisors, released an assessment strategizing how they will tackle childhood chronic diseases, such as obesity and mental health challenges. Part of the report’s focus is on children’s chemical exposure from our foods, which the report says is linked to developmental issues and chronic diseases.   

Amid the report’s release, farm groups have expressed concern over the MAHA agenda’s focus on pesticides. They have said that if the administration starts clamping down on widely used pesticides, crop yields would decline, input costs would surge and food costs would more than double.

‘Farmers are already facing a host of challenges—uncertainty about their access to critical crop protection products shouldn’t be added to the list,’ said Elizabeth Burns-Thompson, Executive Director of the Modern Ag Alliance. ‘Crop protection tools are not only safe, they are essential to food security, affordability, and the survival of family farms all across this country. Losing access to these critical inputs would be a devastating setback to American agriculture.’

Officials from the MAHA Commission sought to reassure farmers at an event releasing their assessment on childhood chronic diseases on Thursday. Agriculture Secretary Brooke Rollins said that ‘at the center’ of the MAHA agenda is ‘making American agriculture great again.’

‘We love our farmers, and we want to pay respect to our farmers. And we always will,’ President Trump added at the Thursday event from the White House. ‘We won the farmers by a lot in the election, and every election, all three elections – and we won by a lot. I will never forget that. And they are foremost in our thought.’

But some farmers are still expressing concern.

 

‘The Make America Healthy Again Report is filled with fear-based rather than science-based information about pesticides. We are deeply troubled that claims of this magnitude are being made without any scientific basis or regard for a long history of EPA expert evaluations of these products,’ the National Corn Grower’s Alliance (NCGA) said. ‘We call on the administration to respect the existing body of science on pesticides and, moving forward, to include America’s farmers in discussion as this process evolves.’ 

According to a statement put out by the Modern Ag Alliance, pesticides are ‘rigorously tested’ by the federal government, noting that in the case of glyphosate – mentioned multiple times in the MAHA report – it is one of the most thoroughly studied pesticides of its kind. 

They said that if the MAHA report drives future policy decisions it would hurt farmers and more than double the cost of food.

‘Without glyphosate—the most widely used weed-fighting tool by U.S. farmers—crop yields would decline, input costs would surge by 150%, and food inflation would more than double,’ the group said. ‘When Sri Lanka prohibited the use of synthetic pesticides and fertilizers in 2021, crop yields fell by over 50%, forcing the government to import massive amounts of food just to meet basic needs. We should be focused on moving American agriculture—and the country—forward.’

Health Secretary Robert F. Kennedy Jr., who has been a vocal opponent against the dangerous health impacts of under-regulated pesticides even before he was the MAHA Commission’s leader, said last week in a Senate hearing that ‘we cannot take any step that will put a single farmer in this country out of business.’

‘There’s a million farmers who rely on glyphosate,’ he said. ‘100% of corn in this country relies on glyphosate. We are not going to do anything to jeopardize that business model.’ 

The MAHA report reiterates the economic importance of protecting farmers, but it also lists glyphosate in an infographic of ‘Chemical Classes and Common Exposure Pathways’ and says research studies have shown it can cause a range of health effects. It also lists atrazine and other chemicals as dangerous to childhood health.   

MAHA Commission officials have said that part of the administration’s focus will be a return to the gold standard of science, but the NCGA said the focus on certain widely-used pesticides, such as atrazine and glyphosate, goes against ‘decades of extensive research and testing.’

‘If the administration’s goal is to bring more efficiency to government, then why is the secretary of Health and Human Services duplicating efforts by raising questions about pesticides that have been answered repeatedly through research and reviews by federal regulatory bodies?’ the group questioned.

Jennifer Galardi, a senior policy analyst focused on health and wellness issues at the Heritage Foundation, took a more balanced view of the MAHA commission’s strategy towards pesticides like glyphosate, noting that it appeared to thread the needle between supporting farmers and trying to ensure America’s food supply is safe and free of chemicals that could impact child health. 

‘The MAHA Commission Report seems to carefully examine competing issues in a very complex agricultural debate: the potential that crop protection tools as they’re referred to in the report may cause adverse health outcomes and the desire to protect the economic interests of farmers and the country,’ Galardi said. ‘However, everyone should agree that the companies that manufacture products such as glyphosate and GMO’s shouldn’t have undue influence over the research upon which sound policy is based. The American public should demand transparency around these decisions.’

Galardi posited that, due to the tension around the issue of pesticides, the MAHA Commission may decide to go after ‘low-hanging fruit,’ such as improving children’s diets and lack of physical activity, which, she said, are big drivers of obesity and metabolic dysfunction.

In response to this article, a USDA spokesperson sent the following statement from Secretary Rollins:

‘We must do more to improve the health outcomes of our kids and families, and President Trump knows agriculture is at the heart of the solution. America’s farmers and ranchers dedicate their lives to the noble cause of feeding their country and the world, and in doing so have created the safest and most abundant and affordable food supply in the world. We are working to make sure our kids and families are consuming the healthiest food we produce. I look forward to continuing to work with Secretary Kennedy and other members of the MAHA Commission to improve our nation’s health.’

White House spokesman Kush Desai, in a separate statement, echoed Rollins’ sentiment about the importance of agriculture and farmers when it comes to executing the MAHA mission. He also reiterated that the MAHA movement is grounded in ‘Gold Standard of Science.’

‘The guiding principle of President Trump’s movement to Make America Healthy Again is the Gold Standard of Science, and everyone from America’s farmers to everyday parents are critical for the success of this movement,’ Desai said. ‘The MAHA Commission’s report is a historic step by our government to, for the first time, comprehensively review the latest evidence and research of what we know – and what we don’t know – is driving the health crisis afflicting America’s children.’

This post appeared first on FOX NEWS

Box stock price has retreated in the past few months as the company has slowed and competition in the core market has risen. It was trading at $31 on Friday, down by 12% from its highest level this year, as focus shifts to the upcoming earnings.

Box growth has stalled

Box is a technology company that provides cloud file storage solutions to customers worldwide.

The company has expanded its business in the past few years. For example, it has invested heavily in artificial intelligence (AI) tools like content management, AI agents, and e-signatures. 

Box’s business has slowed in the past few years, with its annual revenue growing from $770 million in 2021 to $1.09 billion last year. While a 41% growth is a good one, it is much slower than other companies in the software-as-a-service industry.

Box’s main challenge is that it operates in a highly competitive industry. It competes with companies like DropBox, Amazon, Google, and Microsoft, which offer mostly similar solutions.

Many large companies prefer to use one cloud software provider. As such, a company paying for Google Cloud solutions will prefer its Drive solution for storage and sharing solutions. 

Earnings ahead

The next key catalyst for the Box stock price will be the upcoming earnings, which will shed color on its business trajectory. 

The most recent results showed that Box’s revenue rose to $280 million in the fourth quarter of its 2025 fiscal year. It also expanded its gross margin to 81% from 78.4% in the same period last year. 

Analysts expect that Box’s revenue will be $274.4 million, up by 3.8% from the same period last year. The most optimistic analyst see the revenue coming in at $276 million. 

Its earnings per share (EPS) is expected to come in at 26 cents, down from 39 cents a year earlier. 

For the year, analysts anticipate that Box’s revenue will come in at $1.15 billion, up by 5.70% from last year. It will then get to $1.23 billion next year. 

Is Box overvalued or cheap?

A key concern among investors is that Box is relatively overvalued for a company whose business has largely stalled or matured. 

Box has a forward P/E ratio of 26, higher than the S&P 500 Index’s average of 21 even though the index has a faster growth rate. FactSet data shows that the S&P 500 Index had a blended earnings growth rate of 13% in the first quarter. It has a forward EV-to-EBITDA multiple of 13.70, higher than the sector median of 12. 

A good approach for valuing Box is to use the rule-of-40 approach, which compares its growth and margins. The most recent data showed that its revenue growth is about 5%, while its operating margin was 28%, giving it a rule of 40 metric of 33%. 

Box has a free cash flow margin of 28%, meaning that its rule-of-40 metric using this approach is also 33%. A rule of 40 figure of less than 40 is a sign that a company is prioritizing growth over profitability.

Box stock price technical analysis

Box stock chart | Source: TradingView

The daily chart shows that the Box share price peaked at $35.75 in December last year. It formed a double-top pattern at that level with a neckline at $30.56. 

Box shares have moved slightly below the 50-day moving average. They have also formed a head and shoulders pattern, a popular bearish sign.

Therefore, the stock will likely have a bearish breakout after its earnings. If this happens, the next point to watch will be at $31. A move above the resistance level at $32.48 will invalidate the bearish outlook.

The post Box stock price forecast ahead of earnings: buy or sell? appeared first on Invezz